{"id":654735,"date":"2023-06-08T09:12:01","date_gmt":"2023-06-08T09:12:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=654735"},"modified":"2023-06-08T09:12:01","modified_gmt":"2023-06-08T09:12:01","slug":"cytokine-release-syndrome-market-to-register-incremental-growth-during-the-forecast-period-20222032-asserts-delveinsight-key-companies-incyte-genentech-biocon-olatec-therapeutics-novartis","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cytokine-release-syndrome-market-to-register-incremental-growth-during-the-forecast-period-20222032-asserts-delveinsight-key-companies-incyte-genentech-biocon-olatec-therapeutics-novartis_654735.html","title":{"rendered":"Cytokine Release Syndrome Market to Register Incremental Growth During the Forecast Period (2022-2032), Asserts DelveInsight | Key Companies – Incyte, Genentech, Biocon, Olatec Therapeutics, Novartis"},"content":{"rendered":"
\n
\"Cytokine<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
In 2021, the total Cytokine Release Syndrome market size was USD 4.3 million, which is expected to rise during the study period (2019\u20132032). As per DelveInsight, the Cytokine Release Syndrome Market is anticipated to evolve immensely in the coming years owing to the higher usage of CAR-T cell therapies in Hematological cancer patients across 7MM and the expected launch of emerging therapies, such as Itacitinib (Incyte), and Anakinra (Sobi), among others in the market.<\/div>\n

DelveInsight’s “Cytokine Release Syndrome Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Cytokine Release Syndrome market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The report covers emerging Cytokine Release Syndrome drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Cytokine Release Syndrome treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Cytokine<\/p>\n

Cytokine Release Syndrome: An Overview<\/strong><\/p>\n

Cytokine Release Syndrome (CRS) is an acute systemic inflammatory response characterized by fever and multiple organ dysfunction associated with CAR T-cell therapy, therapeutic antibodies, haploidentical allogeneic transplantation, etc. Immune effector cell-associated neurotoxicity syndrome (ICANS) is a neuropsychiatric syndrome that can occur in some patients treated with immunotherapy and may or may not accompany CRS.<\/p>\n

CRS’s complex signs and symptoms result from the effects of cytokines released by the CAR T cells once engaged with the target. Serum levels of inflammatory cytokines are elevated, particularly IL\u20106. The severity of symptoms may correlate with the serum cytokine concentrations and the duration of exposure to the inflammatory cytokines.<\/p>\n

Cytokine Release Syndrome Market Key Facts<\/strong><\/p>\n